卫生技术评估在布地格福与氟替美维快速遴选中的应用与实践

目的: 促进《中国医疗机构药品评价与遴选快速指南》有效落实, 为医疗机构合理采购布地格福及氟替美维提供循证依据。方法: 依据指南制定的百分制评估体系, 通过查阅药品说明书、临床治疗指南, 并检索中国知网、万方、维普、PubMed、Metstr等数据库中相关文献, 收集整理布地格福与氟替美维的相关信息。从有效性、药学特性、安全性、经济性、医保属性、基药属性、贮藏条件、药品效期、药品使用情况及生产企业状况10个方面对两药进行量化评分, 并依据评分结果划分推荐级别。结果: 量化评分, 布地格福与氟替美维分别为84.9分和83.3分。二者均是治疗中重度慢性阻塞性肺疾病(COPD)稳定期患者初始治疗或升阶治疗的一线药物; 布地格福在剂型特色及安全性上略优, 氟替美维在给药频次及特殊人群(重度肝肾功异常)用药方面略优。两药总分均大于80分, 较强推荐进入医疗机构用药目录, 可根据医疗机构用药群体特点酌情选择。结论: 本次卫生技术评估可为医疗机构开展药品评价与遴选提供实践经验, 同时为临床合理使用新型吸入用三联支气管扩张药提供循证依据。

Application and practice of health technology assessment in the rapid selection of budesonide and flutimavir

OBJECTIVE To promote the effective implementation of the "Quick Guide for Drug Evaluation and Selection of Medical Institutions in China", and provide evidence-based basis for the rational procurement of budesonide and flutimavir in medical institutions.METHODS According to the 100-point evaluation system established by the guidelines, by consulting the drug inserts, clinical treatment guidelines, and searching relevant documents in databases such as CNKI, Wanfang, Weipu, PubMed, Metstr, etc., the relevant information of budesonide and flutimavir was collected and sorted out. The two drugs were quantitatively scored in terms of 10 aspects including effectiveness, pharmaceutical properties, safety, economy, medical insurance attributes, basic drug attributes, storage conditions, drug expiration date, drug use and production enterprise status, and divided into the recommendation level according to the score results.RESULTS After quantitative scoring, budesonide and flutimavir were scored 84.9 and 83.3, respectively. Both were the first-line drugs for the initial treatment or upgrade treatment of patients with moderate to severe COPD in stable stage; budesonide was slightly better in terms of dosage characteristics and safety, and flutimavir was better in the frequency of administration and used in special populations (severe liver and kidney function). The total scores of the two drugs were both above 80 points, and both were strongly recommended to enter the drug catalog of medical institutions, and be selected according to the characteristics of drug group of medical institutions.CONCLUSION This health technology assessment can provide medical institutions with practical experience in drug evaluation and selection, and provide evidence for the clinical rational use of new triple bronchodilators.